Chinese innovative drugs

Reports on this topic

Bernstein2026-11-02

Bernstein: China’s innovative drugs gain global clinical validation: Kelun and Hansoh report strong data, while Innovent’s first-line lung cancer treatment remains under scrutiny

Bernstein believes the key change at ESMO 2026 was that several drugs developed in China produced efficacy data in global studies. Kelun-Biotech achieved a positive global phase III result, while Hansoh’s early data sustained the efficacy seen in China; Innovent’s IBI363 faces tests of efficacy durability and safety.

Cailian Press2026-10-30

Chinese innovative drug licensing deals grow as overseas commercialization advances

In the first half of 2026, the total value of China's outbound innovative drug licensing deals reached 99.7 billion US dollars. Guosen Securities believes that increased domestic sales under medical insurance coverage and progress in overseas commercialization will be two drivers of growth for the sector.

Morgan Stanley2026-10-23

Morgan Stanley: COINS draft adds to policy pressure: deal structure takes on greater importance as Chinese innovative drugs go global

Morgan Stanley believes the draft US outbound investment restrictions challenge its more moderate policy assessment from September. Standalone licensing is relatively less affected, while whole-company acquisitions and NewCo collaborations face different constraints. Well-funded companies that can repeatedly monetize projects have an advantage.